OliX Pharmaceuticals,Inc (226950.KQ)

KRW 18430.0

(-6.07%)

Revenue Summary of OliX Pharmaceuticals,Inc

OliX Pharmaceuticals,Inc's latest annual revenue in 2023 was 17.06 Billion KRW , up 83.09% from previous year.
OliX Pharmaceuticals,Inc's latest quarterly revenue in 2024 Q2 was 4.59 Billion KRW , up 498.62% from previous quarter.
OliX Pharmaceuticals,Inc reported a annual revenue of 9.32 Billion KRW in annual revenue 2022, up 153.66% from previous year.
OliX Pharmaceuticals,Inc reported a annual revenue of 3.67 Billion KRW in annual revenue 2021, up 48.5% from previous year.
OliX Pharmaceuticals,Inc reported a quarterly revenue of 4.59 Billion KRW for 2024 Q2, up 498.62% from previous quarter.
OliX Pharmaceuticals,Inc reported a quarterly revenue of 2.25 Billion KRW for 2023 Q1, up 225.76% from previous quarter.

Annual Revenue Chart of OliX Pharmaceuticals,Inc (2023 - 2015)

Historical Annual Revenue of OliX Pharmaceuticals,Inc (2023 - 2015)

Year	Revenue	Revenue Growth
2023	17.06 Billion KRW	83.09%
2022	9.32 Billion KRW	153.66%
2021	3.67 Billion KRW	48.5%
2020	2.47 Billion KRW	118.9%
2019	1.13 Billion KRW	274.28%
2018	302 Million KRW	23.79%
2017	243.96 Million KRW	-37.75%
2016	391.9 Million KRW	-56.82%
2015	907.61 Million KRW	0.0%

Year	Revenue	Revenue Growth
2024 Q1	768.38 Million KRW	-92.69%
2024 Q2	4.59 Billion KRW	498.62%
2023 Q1	2.25 Billion KRW	225.76%
2023 FY	17.06 Billion KRW	83.09%
2023 Q3	2.02 Billion KRW	-11.04%
2023 Q2	2.27 Billion KRW	0.87%
2023 Q4	10.5 Billion KRW	418.79%
2022 Q3	4.43 Billion KRW	138.34%
2022 Q1	2.32 Billion KRW	164.65%
2022 FY	9.32 Billion KRW	153.66%
2022 Q4	692.76 Million KRW	-84.39%
2022 Q2	1.86 Billion KRW	-20.05%
2021 Q1	995.71 Million KRW	-20.25%
2021 FY	3.67 Billion KRW	48.5%
2021 Q4	879.83 Million KRW	9.56%
2021 Q2	995.71 Million KRW	0.0%
2021 Q3	803.09 Million KRW	-19.34%
2020 Q3	907.95 Million KRW	566.57%
2020 Q2	136.21 Million KRW	-25.0%
2020 Q1	181.61 Million KRW	-38.1%
2020 Q4	1.24 Billion KRW	37.51%
2020 FY	2.47 Billion KRW	118.9%
2019 Q2	373.26 Million KRW	220.61%
2019 Q1	116.42 Million KRW	-42.37%
2019 Q3	347.26 Million KRW	-6.97%
2019 Q4	293.38 Million KRW	-15.52%
2019 FY	1.13 Billion KRW	274.28%
2018 Q4	202 Million KRW	206.05%
2018 FY	302 Million KRW	23.79%
2018 Q3	66 Million KRW	94.14%
2018 Q2	33.99 Million KRW	0.0%
2018 Q1	- KRW	0.0%
2017 FY	243.96 Million KRW	-37.75%
2016 FY	391.9 Million KRW	-56.82%
2015 FY	907.61 Million KRW	0.0%

Peer Revenue Comparison of OliX Pharmaceuticals,Inc

Name	Revenue	Revenue Difference
HLB Co., Ltd.	42.9 Billion KRW	60.224%
iNtRON Biotechnology, Inc.	9.58 Billion KRW	-78.023%
BINEX Co., Ltd.	154.82 Billion KRW	88.978%
Bioneer Corporation	263.23 Billion KRW	93.518%
Anterogen.Co.,Ltd.	6.5 Billion KRW	-162.517%
MEDIPOST Co., Ltd.	68.64 Billion KRW	75.141%
CrystalGenomics, Inc.	4.87 Billion KRW	-249.774%
Helixmith Co., Ltd	4.2 Billion KRW	-306.135%
Chabiotech Co.,Ltd.	953.95 Billion KRW	98.211%
Medy-Tox Inc.	221.12 Billion KRW	92.283%
Peptron, Inc.	3.34 Billion KRW	-410.617%
Amicogen, Inc.	159.9 Billion KRW	89.328%
Genexine, Inc.	4.42 Billion KRW	-285.492%
HLB Therapeutics Co.,Ltd.	53.74 Billion KRW	68.252%
LegoChem Biosciences, Inc.	34.14 Billion KRW	50.025%
ALTEOGEN Inc.	96.52 Billion KRW	82.321%
PharmaResearch Co., Ltd.	261.01 Billion KRW	93.462%
SillaJen, Inc.	3.93 Billion KRW	-333.152%
JETEMA, Co., Ltd.	58.71 Billion KRW	70.938%
Genomictree Inc.	3.41 Billion KRW	-399.246%
MedPacto, Inc.	- KRW	-Infinity%
D&D Pharmatech	18.67 Billion KRW	8.635%
EASY BIO,Inc.	165.38 Billion KRW	89.682%
GI Innovation, Inc.	5.31 Billion KRW	-220.826%